JPJuliana Piedade

Juliana Piedade

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juliana Piedade has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Natural History of Hepatosplenic Schistosomiasis (HSS) Non–Cirrhotic Portal Hypertension (NCPH): Influence of Gastrointestinal Bleeding and Decompensation in Prognosis

    by Zulane S. T. Veiga, Flávia F. Fernandes, Lívia Guimarães, Juliana Piedade, Gustavo Henrique S. Pereira

    Background: Hepatosplenic schistosomiasis (HSS) is a peculiar form of non-cirrhotic portal hypertension (NCPH). Although HSS patients present normal hepatic function, some evolve signs of hepatocellular failure and features of decompensated cirrhosis. The natural history of HSS-NCPH is unknown. Methods: A retrospective study was conducted that evaluated patients who fulfilled clinical-laboratorial criteria for HSS. Results: A total of 105 patients were included. Eleven patients already presented with decompensated disease and had lower transplant-free survival at 5 years than those without (61% vs. 95%, p = 0.015). Among 94 patients without prior decompensation, the median follow-up was 62 months and 44% of them had varicose bleeding (two or more episodes in 27%). Twenty-one patients presented at least one episode of decompensation (10-year probability 38%). Upon multivariate analysis, varicose bleeding and higher bilirubin levels were associated with decompensation. The 10-year probability of survival was 87%. Development of decompensation and age were predictive of mortality. Conclusion: HSS is characterized by multiple episodes of GI bleeding, a high probability of decompensation and reduced survival at the end of the first decade. Decompensation is more common in patients with varicose esophageal bleeding and is associated with lower survival.


  • Open Access

    Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort

    by Lívia Md Victor, Renata Perez, Flávia Fernandes, Juliana Md Piedade, Cristiane A. Villela-Nogueira, Gustavo Pereira

    Real-life data on the HCV treatment with direct-acting agents in patients with decompensated cirrhosis are scarce. Study to investigate the effectiveness and safety of sofosbuvir-containing regimens in a prospective cohort of patients with HCV decompensated cirrhosis. A total of 150 patients were enrolled (64% male, 84% genotype 1 with a mean age of 61 ± 9 years). The median MELD was 12, and 79% were Child-PughB. Most patients were treated with sofosbuvir and daclatasvir (98%) with ribavirin in 27%. The overall intention to treat SVR12 was 91% (137/150). The most frequent adverse event was anemia (17%), 73% associated with ribavirin. Twenty-one (14%) patients experienced renal dysfunction, 81% AKI I, and 1 discontinued treatment. Thirty-five (23%) patients presented at least 1 infectious episode, mainly respiratory tract infection (29%). Thirty-three patients (22%) had at least 1 episode of cirrhosis decompensation throughout treatment, particularly worsening of previous ascites in 19%. Nine patients died, and among those, 7 patients died from sepsis. The probability of decompensation in 28, 90 and 180 days was 4%, 19% and 25%. During treatment, infection (OR 2.24; 95 CI 1.09–4.61; P = .03) was a predictor of cirrhosis decompensation, and baseline MELD and CHILD ≥ B8 were both associated with infection. In decompensated cirrhosis, the overall virological response was high with mild adverse events. However, this population had a high frequency of liver-associated decompensation and infections.

  • Open Access

    Systemic Inflammatory Response Syndrome in Patients Hospitalized for Acute Decompensation of Cirrhosis

    by Ariane Borgonovo, Caroline Baldin, Dariana C. Maggi, Livia Victor, Emilia T. O. Bansho, Juliana Piedade, Letícia M. Wildner, Lívia Guimarães, Maria L. Bazzo, Tamires Rocha, et al.

    Background. Although recently challenged, systemic inflammatory response syndrome (SIRS) criteria are still commonly used in daily practice to define sepsis. However, several factors in liver cirrhosis may negatively impact its prognostic ability. Goals. To investigate the factors associated with the presence of SIRS, the characteristics of SIRS related to infection, and its prognostic value among patients hospitalized for acute decompensation of cirrhosis. Study. In this cohort study from two tertiary hospitals, 543 patients were followed up, up to 90 days. Data collection, including the prognostic models, was within 48 hours of admission. Results. SIRS was present in 42.7% of the sample and was independently associated with upper gastrointestinal bleeding (UGB), ACLF, infection, and negatively related to beta‐blockers. SIRS was associated with mortality in univariate analysis, but not in multiple Cox regression analysis. The Kaplan–Meier survival probability of patients without SIRS was 73.0% and for those with SIRS was 64.7%. The presence of SIRS was not significantly associated with mortality when considering patients with or without infection, separately. Infection in SIRS patients was independently associated with Child‐Pugh C and inversely related to UGB. Among subjects with SIRS, mortality was independently related to the presence of infection, ACLF, and Child‐Pugh C. Conclusions. SIRS was common in hospitalized patients with cirrhosis and was of no prognostic value, even in the presence of infection.


  • COVID-19: An Overview of Worldwide Recommendations for Management of Patients With Liver Diseases or Liver Transplantation

    by Hugo Perazzo, Juliana Piedade, Rodolfo Castro, Laura Pinto, Valdiléa G. Veloso, Beatriz Grinsztejn, Gustavo Pereira, Flavia F. Fernandes


  • Effectiveness of direct‐acting agents for chronic hepatitis C treatment in South America: A systematic review and meta‐analysis

    by Elio C. Castro Filho, Juliana Piedade, Rodolfo Castro, Paula M. Luz, Flavia Fernandes, Beatriz Grinsztejn, Valdilea G. Veloso, Gustavo Henrique Pereira, Hugo Perazzo

    The effectiveness of direct‐acting agents (DAAs) for hepatitis C treatment in limited‐resource settings remains unclear. We estimated the pooled sustained virological response rates of DAA therapy in South America. We searched online databases for studies that reported 12‐weeks sustained virological response (SVR12) to hepatitis C virus (HCV) treatment in individuals living in South America. Pooled SVR12 in intention‐to‐treat (ITT) and per‐protocol were estimated. Additionally, using all studies with available data, the pooled relative risk (RR) of SVR12 using a random‐effects model (DerSimonian‐Laird) was estimated to compare effectiveness of DAAs in patients with or without cirrhosis, HIV co‐infection or previous HCV therapy. Heterogeneity was assessed using the I2 statistics. We identified 20 studies [14 manuscripts and 6 conference abstracts] comprising 7,393 individuals from five countries [Brazil (n=11), Argentina (n=4), Chile (n=1), Colombia (n=1) and Peru (n=1)] and two South‐American collaborations. The pooled overall SVR12 rates [95% confidence interval (CI)] were 92.6% [90.2‐94.7] and 95.5% [94.3‐96.6] by ITT (11 studies; n=4,153; I2=84.2%) and per‐protocol analysis (15 studies; n=4,833; I2=64.5%), respectively. The RR of SVR12 was similar in patients with or without HIV co‐infection [4 studies; RR=1.03(0.99‐1.07)] and those naive compared to treatment experimented‐individuals [9 studies; RR=1.01(1.00‐1.03)], but significantly higher in patients without cirrhosis compared to those with cirrhosis [11 studies; RR=1.04(1.02‐1.05), p<0.001]. DAAs are highly effective for HCV treatment in South America. The use of DAAs should be considered in limited‐resource settings to decrease the burden of liver disease in HCV‐infected patients. PROSPERO[CRD 42019134603]


  • Combination and sequential evaluation of acute-on-chronic liver failure (ACLF) and hyponatremia and prognosis in cirrhotic patients

    by Gustavo Pereira, Caroline Baldin, Juliana Piedade, Vanessa Reis, Tatiana Valdeolivas, Lívia Victor, Lívia Guimarães, Joana Duarte, Zulane Veiga, Camila Alcântara, et al.


  • Effectiveness of direct‐acting agents for hepatitis C and liver stiffness changing after sustained virological response

    by Flavia F Fernandes, Juliana Piedade, Livia Guimaraes, Estevao P Nunes, Ursula B Chaves, Rafaela V Goldenzon, Sandra W Cardoso, Joana Duarte, Beatriz Grinsztejn, Valdilea G Veloso, et al.

    Background and Aim: Few studies have evaluated sustained virological response (SVR) rates by direct‐acting agents (DAAs) and liver stiffness measurement (LSM) changing post‐SVR in limited‐resource settings. We aimed to describe the effectiveness of DAAs for hepatitis C virus treatment and to assess the changing of LSM post‐SVR.Methods: This retrospective study analyzed data of consecutive hepatitis C virus‐infected patients treated by DAAs from 2015 to 2017 in two tertiary centers in Brazil. SVR rates were reported by intention‐to‐treat and per‐protocol analyses. LSM by transient elastography performed before treatment and post‐SVR was compared, and logistic regression models were performed.Results: Six hundred seventy‐one patients (63% female, 62 years [55–68], 89% genotype 1, 8% HIV co‐infected, and 64% with cirrhosis) were included. Most patients were treated by sofosbuvir/daclatasvir ± ribavirin (74%) and sofosbuvir/simeprevir ± ribavirin (21%). SVR rates (95% confidence interval [CI]) were 94.6% (92.7–96.1) and 97.8% (96.4–98.7) for intention‐to‐treat and per‐protocol analyses, respectively. The leading adverse event was anemia (9.6% [95% CI 7.6–12.1]). Pretreatment and post‐SVR12 LSM were available in 400 patients. LSM had significantly decreased after SVR (13.6 kPa [interquartile range, 10.0–21.6] vs 10.2 kPa [7.0–17.6], P < 0.001). A total of 167 patients (42%) decreased at least 30% of LSM post‐SVR. The absence of type 2 diabetes (odds ratio = 1.52 [95% CI 1.05–2.21], P = 0.028) and presence of platelet count ≥ 150 × 109/mm3 (odds ratio = 1.75 [1.23–2.50], P = 0.002) were independently associated with a significant LSM regression (≥ 30%) post‐SVR.Conclusion: DAAs were highly effective and safe, and LSM significantly decreased after SVR in a real‐life cohort in Brazil. The absence of type 2 diabetes and presence of high platelet count were independently associated with LSM decrease post‐SVR.